Stops False Drug Approval Delays

Biosimilar Red Tape Elimination Act

To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.

Expedited Access to Biosimilars Act